Research shows HPV vaccine effective in preventing cancer

In 2008, healthcare providers were pushing for young women to get the HPV vaccine to reduce their chances of developing cervical cancers, and eight years later, it seems as though it worked.

A new study from Cincinnati Children’s Hospital Medical Center in Ohio, published in the journal Clinical Infectious Diseases, shows that the prevalence of HPV in vaccinated women dropped more than 90 percent and more than 30 percent in unvaccinated women from 35 percent to just 3 percent.

"Our study demonstrates high vaccine effectiveness in a community setting, even among sexually experienced young woman who may already have been exposed to HPV," said Jessica Kahn, MD, the lead author on the study and a physician in the Division of Adolescent and Transition Medicine Cincinnati Children's, in a statement. “The substantial decrease in vaccine-type HPV was likely due to excellent HPV vaccine efficacy and high vaccination rates in this population."

In the study, the researchers examined more than 1,180 sexually experienced women in Cincinnati. They were divided into three groups: one before the vaccine was introduced, one at three years after introduction and then one at seven years.

"It will be important for us to assess effectiveness over an even longer period of time to determine whether it is sustained, but these results suggest that vaccination programs could have a substantial population-level impact on rates of HPV-related cancers," Kahn said.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”